Cargando…

Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma

AIM: To investigate if pre-treatment platelet counts could provide prognostic information in patients with rectal adenocarcinoma that received neo-adjuvant treatment. METHODS: Platelet number on diagnosis of stage II and III rectal cancer was evaluated in 51 patients receiving neo-adjuvant treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Steele, Morgan, Voutsadakis, Ioannis A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241527/
https://www.ncbi.nlm.nih.gov/pubmed/28144399
http://dx.doi.org/10.4251/wjgo.v9.i1.42
_version_ 1782496200201601024
author Steele, Morgan
Voutsadakis, Ioannis A
author_facet Steele, Morgan
Voutsadakis, Ioannis A
author_sort Steele, Morgan
collection PubMed
description AIM: To investigate if pre-treatment platelet counts could provide prognostic information in patients with rectal adenocarcinoma that received neo-adjuvant treatment. METHODS: Platelet number on diagnosis of stage II and III rectal cancer was evaluated in 51 patients receiving neo-adjuvant treatment and for whom there were complete follow-up data on progression and survival, as well as pathologic outcome at the time of surgery. Pathologic responses on the surgical specimen of patients with lower platelet counts (150-300 × 10(9)/L) were compared with these of patients with higher platelet counts (> 300 × 10(9)/L) by the χ(2) test. Overall and progression free survival Kaplan-Meier curves of the two groups were constructed and compared with the Log-Rank test. RESULTS: A significant difference was present between the two groups in regards to pathologic response with patients with lower platelet counts being more likely to exhibit a good or complete response to neo-adjuvant treatment than patients with higher platelet counts (P = 0.015). Among other factors evaluated, there was also a significant difference between the carcinoembryonic antigen (CEA) at presentation of patients that exhibited a good or complete response and those that had no response or a minimal to moderate response. Patients with a good or complete response were more likely to present with a CEA of less than 5 μg/L (P = 0.00066). There was no significant difference in overall and progression free survival between the two platelet count groups (Log-Rank tests P = 0.42 and P = 0.35, respectively). CONCLUSION: In this retrospective analysis of stage II and III rectal cancer patients, platelet counts at the time of diagnosis had prognostic value for neo-adjuvant treatment pathologic response. Pre-treatment CEA also held prognostic value in regards to treatment effect.
format Online
Article
Text
id pubmed-5241527
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-52415272017-01-31 Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma Steele, Morgan Voutsadakis, Ioannis A World J Gastrointest Oncol Retrospective Study AIM: To investigate if pre-treatment platelet counts could provide prognostic information in patients with rectal adenocarcinoma that received neo-adjuvant treatment. METHODS: Platelet number on diagnosis of stage II and III rectal cancer was evaluated in 51 patients receiving neo-adjuvant treatment and for whom there were complete follow-up data on progression and survival, as well as pathologic outcome at the time of surgery. Pathologic responses on the surgical specimen of patients with lower platelet counts (150-300 × 10(9)/L) were compared with these of patients with higher platelet counts (> 300 × 10(9)/L) by the χ(2) test. Overall and progression free survival Kaplan-Meier curves of the two groups were constructed and compared with the Log-Rank test. RESULTS: A significant difference was present between the two groups in regards to pathologic response with patients with lower platelet counts being more likely to exhibit a good or complete response to neo-adjuvant treatment than patients with higher platelet counts (P = 0.015). Among other factors evaluated, there was also a significant difference between the carcinoembryonic antigen (CEA) at presentation of patients that exhibited a good or complete response and those that had no response or a minimal to moderate response. Patients with a good or complete response were more likely to present with a CEA of less than 5 μg/L (P = 0.00066). There was no significant difference in overall and progression free survival between the two platelet count groups (Log-Rank tests P = 0.42 and P = 0.35, respectively). CONCLUSION: In this retrospective analysis of stage II and III rectal cancer patients, platelet counts at the time of diagnosis had prognostic value for neo-adjuvant treatment pathologic response. Pre-treatment CEA also held prognostic value in regards to treatment effect. Baishideng Publishing Group Inc 2017-01-15 2017-01-15 /pmc/articles/PMC5241527/ /pubmed/28144399 http://dx.doi.org/10.4251/wjgo.v9.i1.42 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Retrospective Study
Steele, Morgan
Voutsadakis, Ioannis A
Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
title Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
title_full Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
title_fullStr Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
title_full_unstemmed Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
title_short Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
title_sort pre-treatment platelet counts as a prognostic and predictive factor in stage ii and iii rectal adenocarcinoma
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241527/
https://www.ncbi.nlm.nih.gov/pubmed/28144399
http://dx.doi.org/10.4251/wjgo.v9.i1.42
work_keys_str_mv AT steelemorgan pretreatmentplateletcountsasaprognosticandpredictivefactorinstageiiandiiirectaladenocarcinoma
AT voutsadakisioannisa pretreatmentplateletcountsasaprognosticandpredictivefactorinstageiiandiiirectaladenocarcinoma